MAGE-A4 antigenic peptides and uses thereof

Details MAGE-A4 antigenic peptides and uses thereof MAGE-A4 antigenic peptides and uses thereof

2007-12-25

2007-12-25

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C530S300000, C530S350000, C424S185100

Reexamination Certificate

active

10218095

ABSTRACT:
The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5487974 (1996-01-01), Boon-Falleur et al.
patent: 5571711 (1996-11-01), van der Bruggen et al.
patent: 5587289 (1996-12-01), Lurquin et al.
patent: 5589334 (1996-12-01), Coulie et al.
patent: 5610013 (1997-03-01), Van den Eynde et al.
patent: 5620886 (1997-04-01), Brichard et al.
patent: 5629166 (1997-05-01), van der Bruggen et al.
patent: WO 92/20356 (1992-11-01), None
patent: WO 96/10577 (1996-11-01), None
Roitt et al, Immunology, 4th ed, 1998, Mosby, New York, pp. 1.8, 7.10.
Bowie et al (Science, 1990, 257:1306-1310).
Long et al, Biochemical and biophysical research communications, Nov. 2, 1999, 264(3): p. 902-8.
Ye et al, J med chem. 1995, 38: 4270-4275.
Burgess et al, J of Cell Bio. 111:2129-2138, 1990.
Lazar et al, Molecular and Cellular Biology, 1988, 8:1247-1252.
Smith RT, 1994, Clin Immunol, 41(4): 841-849.
Boon (Adv Can Res, 1992, 58:177-210).
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Kirkin et al, 1998, APMIS, 106 : 665-679.
White et al, 2001, Ann Rev Med, 52: 125-145.
Bergmann et al, 1994 (J Virol, 68(8): 5306-5310).
Eisenlohr et al, 1992 (J Exp Med, 175:481-487).
Shastri et al, 1995 (J Immunol, 155: 4339-4346).
Guo et al, 1992 (Nature, 360: 364-366).
Barinaga, “Getting Some ‘Backbone’: How MHC Binds Peptides,”Science1992, 257: 880-881.
Chaux et al., “Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+T Lymphocytes,”J. Exp. Med.1999, 189, 5: 767-777.
Chen et al., “High frequency of expression of MAGE genes in human hepatocellular carcinoma,”Liver1999, 19: 110-1104.
Chomez et al., “Overview of the MAGE Gene Family with the Identification of All Human Mebers of the Family,”Cancer Research2001, 61: 5544-5551.
De Plaen et al., “Structure, chromosomal localization, and expression of 12 genes of the MAGE family,”Immunogenetics1994, 40: 360-369.
De Plaen et al., “Alternative Promoters of Gene MAGE4a,”Genomics1997, 40: 305-313.
Dalerba et al., “MAGE, BAGE and GAGE Gene Expression in Human Rhabdomyosarcomas,”Int. J. Cancer2001, 93: 85-90.
Duffour et al., “A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes,”Eur. J. Immunol.1999, 29: 3329-3337.
Espevik et al., “A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes,”Journal of Immunological Methods1986, 95: 99-105.
Falk et al., “Peptide motifs of HLA-B35 and -B37 molecules,”Immunogenetics1993, 38: 161-162.
Fremont et al., “Crystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2Kb,”Science1992, 257: 919-927.
Haas Jr. et al., “Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis,”American Journal of Reproductive Immunology and Microbiology1988, 18: 47-51.
Hansen et al., “Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill,”Journal of Immunological Methods1989, 119: 203-210.
Hunt et al., “Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry,”Science1992, 255: 1261-1263.
Jäger et al., “Clinical cancer vaccine trials,”Curr. Opin. Immunol.2002, 14: 178-182.
Latron et al., “A Critical Role for Conserved Residues in the Cleft of HLA-A2 in Presentation of a Nonapeptide to T Cells,”Science1992, 257: 964-967.
Lonchay et al., “Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen,”Proc. Natl. Acad. Sci. USA2004, 101 suppl. 2: 14631-14638.
Lucas et al., “Identification of a New MAGE Gene with Tumor-specific Expression by Representational Difference Analysis,”Cancer Research1998, 58: 743-752.
Luiten et al., “A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes,”Tissue Antigens2000, 55: 149-152.
Lurquin et al., “Two Members of the Human MAGEB Gene Family Located in Xp21.3 Are Expressed in Tumors of Various Histological Origins,”Genomics1997, 46: 397-408.
Lurquin et al., “Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melonoma patient vaccinated with a MAGE tumor antigen,”The Journal of Experimental Medicine2005, 201, 2: 249-257.
Male et al.,Advanced Immunology(J.P. Lipincott Company, 1987), chapters 6-10.
Matsumura et al., “Emerging Principles for the Recongnition of Peptide Antigens by MHC Class I Molecules,”Science1992, 257: 927-934.
Marchand et al., “Biological and clinical developments in melanoma vaccines,”Exp. Opin. Biol. Ther.2001, 1,3: 497-510.
Marchand et al., “Tumor Regressions Observed in Patients with Metastatic Melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1,”Int. J. Cancer1999, 80: 219-230.
Mavilio et al., “Peripheral Blood Lymphocytes as Target Cells of Retroviral Vector-Mediated Gene Transfer,”Blood1994: 83, 7: 1988-1997.
Rammensee et al., “MHC ligands and peptide motifs: first listing,”Immunogenetics1995, 41: 178-228.
Schultz et al., “A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes,”Tissue Antigens2001, 57: 103-109.
Thurner et al., “Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma,”J. Exp. Med.1999, 190, 11: 1669-1678.
Traversari et al., “A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E,”J. Exp. Med.1992, 176: 1453-1457.
Traversari et al., “Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes,”Immunogenetics1992, 35: 145-152.
Van Der Bruggen et al., “Tumor-specific shared antigenic peptides recognized by human T cells,”Immunological Reviews2002, 188: 51-64.
Van Der Bruggen et al., “Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601*,”Eur. J. Immunol.1994, 24: 2134-2140.
Van Der Bruggen et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma,”Science1991, 254: 1643-1647.
Van Snick et al., “Interleukin-HP1, a T Cell-Derived Hybridoma Growth Factor that Supports the In Vitro Growth of Murine Plasmacytomas,”J. Exp. Med.1987, 165: 641-649.

Affiliated with

Also associated with

Rating

MAGE-A4 antigenic peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MAGE-A4 antigenic peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAGE-A4 antigenic peptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3838067